Cost-Effectiveness of Empagliflozin (Jardiance®) In The Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) In Turkey Based Empa-Reg Outcome Data
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.457
https://www.valueinhealthjournal.com/article/S1098-3015(17)30791-X/fulltext
Title :
Cost-Effectiveness of Empagliflozin (Jardiance®) In The Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) In Turkey Based Empa-Reg Outcome Data
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30791-X&doi=10.1016/j.jval.2017.08.457
First page :
A479
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
430